Drug Trial Radar · NCT03772678
A Phase I Study to Evaluate LSALT Peptide
Last checked: Nov 19, 2026Latest source record: Nov 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Jun 27, 2019
Primary completion
Mar 31, 2020
Study completion Mar 31, 2020
Sponsor
- Lead sponsor
- Arch Biopartners Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 11, 2018
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A phase I double-blind, placebo-controlled, randomized, single and multiple ascending dose finding study to evaluate the safety and pharmacokinetic profile of LSALT peptide in healthy participants
Conditions
- None - Study is to Determine Safety in Healthy Participants
Interventions
LSALT peptideDrug
novel 16 amino acid peptide
0.9% SalineOther
saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety EvaluationTime frame: Within 21 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network Ltd.
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.